<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:41:30Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3162591" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3162591</identifier><datestamp>2011-09-01</datestamp><setSpec>plosone</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3162591</article-id>
      <article-id pub-id-type="pmcid">PMC3162591</article-id>
      <article-id pub-id-type="pmc-uid">3162591</article-id>
      <article-id pub-id-type="pmid">21887377</article-id>
      <article-id pub-id-type="pmid">21887377</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-11-06082</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0024100</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Developmental Biology</subject>
            <subj-group>
              <subject>Cell Differentiation</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Molecular cell biology</subject>
            <subj-group>
              <subject>Cellular Structures</subject>
              <subj-group>
                <subject>Cell Nucleus</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Gene expression</subject>
              <subj-group>
                <subject>DNA transcription</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Identification of a Phosphorylation-Dependent Nuclear Localization Motif in Interferon Regulatory Factor 2 Binding Protein 2</article-title>
        <alt-title alt-title-type="running-head">Phosphorylation Controls IRF2BP2 Nuclear Import</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Teng</surname>
            <given-names>Allen C. T.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Al-montashiri</surname>
            <given-names>Naif A. M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>Brian L. M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lou</surname>
            <given-names>Philip</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ozmizrak</surname>
            <given-names>Pinar</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Hsiao-Huei</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stewart</surname>
            <given-names>Alexandre F. R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
          <xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<label>1</label>
<addr-line>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada</addr-line>
</aff>
      <aff id="aff2">
<label>2</label>
<addr-line>Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada</addr-line>
</aff>
      <aff id="aff3">
<label>3</label>
<addr-line>University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada</addr-line>
</aff>
      <aff id="aff4">
<label>4</label>
<addr-line>Ottawa Hospital Research Institute, Ottawa, Ontario, Canada</addr-line>
</aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Pierre-Antoine</surname>
            <given-names/>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">UniversitÃ© Paris-Diderot, France</aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>astewart@ottawaheart.ca</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: ACTT AFRS. Performed the experiments: ACTT NAMA-m BLMC PL PO H-HC. Analyzed the data: ACTT H-HC AFRS. Contributed reagents/materials/analysis tools: H-HC. Wrote the paper: ACTT H-HC AFRS.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <volume>6</volume>
      <issue>8</issue>
      <elocation-id>e24100</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>4</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>7</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Teng et al.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a muscle-enriched transcription factor required to activate vascular endothelial growth factor-A (VEGFA) expression in muscle. IRF2BP2 is found in the nucleus of cardiac and skeletal muscle cells. During the process of skeletal muscle differentiation, some IRF2BP2 becomes relocated to the cytoplasm, although the functional significance of this relocation and the mechanisms that control nucleocytoplasmic localization of IRF2BP2 are not yet known.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>Here, by fusing IRF2BP2 to green fluorescent protein and testing a series of deletion and site-directed mutagenesis constructs, we mapped the nuclear localization signal (NLS) to an evolutionarily conserved sequence <sup>354</sup>ARKRKPSP<sup>361</sup> in IRF2BP2. This sequence corresponds to a classical nuclear localization motif bearing positively charged arginine and lysine residues. Substitution of arginine and lysine with negatively charged aspartic acid residues blocked nuclear localization. However, these residues were not sufficient because nuclear targeting of IRF2BP2 also required phosphorylation of serine 360 (S360). Many large-scale phosphopeptide proteomic studies had reported previously that serine 360 of IRF2BP2 is phosphorylated in numerous human cell types. Alanine substitution at this site abolished IRF2BP2 nuclear localization in C<sub>2</sub>C<sub>12</sub> myoblasts and CV1 cells. In contrast, substituting serine 360 with aspartic acid forced nuclear retention and prevented cytoplasmic redistribution in differentiated C<sub>2</sub>C<sub>12</sub> muscle cells. As for the effects of these mutations on VEGFA promoter activity, the S360A mutation interfered with VEGFA activation, as expected. Surprisingly, the S360D mutation also interfered with VEGFA activation, suggesting that this mutation, while enforcing nuclear entry, may disrupt an essential activation function of IRF2BP2.</p>
        </sec>
        <sec>
          <title>Conclusions/Significance</title>
          <p>Nuclear localization of IRF2BP2 depends on phosphorylation near a conserved NLS. Changes in phosphorylation status likely control nucleocytoplasmic localization of IRF2BP2 during muscle differentiation.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Interferon regulatory factor 2 binding protein 2 (IRF2BP2), together with the related protein IRF2BP1, were initially discovered as interacting partners to interferon regulatory factor 2 (IRF2) in a yeast two-hybrid screening assay <xref rid="pone.0024100-Childs1" ref-type="bibr">[1]</xref>. A third homolog of IRF2BP2 called enhanced at puberty 1 (EAP1, formerly known as C14orf4) is expressed in the mediobasal hypothalamus and plays a critical function in regulating the female reproductive neuroendocrine axis <xref rid="pone.0024100-Heger1" ref-type="bibr">[2]</xref>. All three are nuclear proteins.</p>
      <p>Structurally, IRF2BP2 is encoded by 2 exons producing 3 alternatively spliced proteins IRF2BP2a of 587, IRF2BP2b of 561 and IRF2BP2c of 163 amino acids depending on the use of alternative donor (2a and 2b) and acceptor (2c) splice sites. IRF2BP2a and b isoforms have a Zinc-finger motif at their N-terminus, missing in the IRF2BP2c isoform, and a C3HC4 RING-finger motif at their C-terminus. The function of the Zinc-finger motif appears to enable homo- and hetero-dimerization between different members of the IRF2BP2 family<xref rid="pone.0024100-Yeung1" ref-type="bibr">[3]</xref>. The RING-finger motif from amino acids 456â587 is sufficient to interact with IRF2 <xref rid="pone.0024100-Childs1" ref-type="bibr">[1]</xref> and also with nuclear receptor interacting factor 3 (NRIF3) <xref rid="pone.0024100-Tinnikov1" ref-type="bibr">[4]</xref>. IRF2BP2 was described as a co-repressor of IRF2, inhibiting the expression of interferon-responsive genes.</p>
      <p>The tumor suppressor p53 binds to the IRF2BP2 promoter and transactivates its expression in response to actinomycin D treatments in both cervical carcinoma (HeLa) and osteosarcoma (U2OS) <xref rid="pone.0024100-Koeppel1" ref-type="bibr">[5]</xref>. Increased endogenous IRF2BP2 protein levels in turn suppress the induction of apoptosis after genotoxic stress. Specifically, IRF2BP2 suppresses the transactivation activity of p53 on both Bax and p21 promoters. Anti-apoptotic activity was also ascribed to IRF2BP2 due to its modulation of a death domain in NRIF3 <xref rid="pone.0024100-Yeung1" ref-type="bibr">[3]</xref>â<xref rid="pone.0024100-Tinnikov1" ref-type="bibr">[4]</xref>.</p>
      <p>We identified IRF2BP2 as a cofactor of VGLL4 in a yeast two-hybrid screen <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>. VGLL4 is itself a cofactor of the TEAD transcription factors <xref rid="pone.0024100-Chen1" ref-type="bibr">[7]</xref>, that play a critical role controlling gene expression in skeletal, cardiac and smooth muscle cells <xref rid="pone.0024100-Yoshida1" ref-type="bibr">[8]</xref>. We showed that transient over-expression of IRF2BP2 and TEAD1 could induce the expression of vascular endothelial growth factor-A (VEGF-A) in murine C<sub>2</sub>C<sub>12</sub> myoblasts <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>. We also discovered that IRF2BP2 protein levels increase in response to ischemia in hindlimb and cardiac muscle. Whereas endogenous IRF2BP2 found in murine C<sub>2</sub>C<sub>12</sub> myoblasts is nuclear, following ischemia, IRF2BP2 is mostly cytoplasmic. This discrepancy suggests a potential mechanism for modulating IRF2BP2 translocation across the nuclear membrane.</p>
      <p>Nucleocytoplasmic shuttling is a carefully regulated process controlling the import and export of both mRNA and proteins <xref rid="pone.0024100-Adam1" ref-type="bibr">[9]</xref>â<xref rid="pone.0024100-Germain1" ref-type="bibr">[10]</xref>. To cross the nuclear membrane, polypeptides use different mechanisms for translocation; small proteins (&lt;40kDa) diffuse through the membrane passively while large proteins (&gt;40kDa) are actively transferred by the nuclear pore complexes (NPCs) on the nuclear membrane <xref rid="pone.0024100-Paine1" ref-type="bibr">[11]</xref>. Nucleocytoplasmic transport encompasses many hierarchical steps. To initiate the process, a cargo protein heterodimerizes with karyopherin via classical nuclear localization signals (NLS; K-K/R-X-K/R, Kâ=â lysine, Râ=â arginine, Xâ=â any amino acids) <xref rid="pone.0024100-Adam1" ref-type="bibr">[9]</xref>, <xref rid="pone.0024100-Zanta1" ref-type="bibr">[12]</xref>. Next, physical binding of the guanosine-5â²-diphosphate (GDP)-bound Ran molecule to the complex signals to cross the membrane. Once inside the nucleus, GTP exchange factor (GEF) facilitates the GDP to guanosine-5â²-triphosphate (GTP) exchange process, leading to the release of cargo protein. One of the classical examples of a nuclear shuttled protein is the T-antigen of SV40 <xref rid="pone.0024100-Miyamoto1" ref-type="bibr">[13]</xref>.</p>
      <p>In this report, we used deletion and site-directed mutagenesis to localize a conserved functional NLS in IRF2BP2. In addition, we found that phosphorylation of serine residue 360 (S360) adjacent to the NLS is also involved in controlling the nuclear entry of the protein. <italic>In silico</italic> database mining revealed that this serine residue is phosphorylated in IRF2BP2 and IRF2BP1, and sequence comparisons revealed that this motif is conserved in all members of the IRF2BP2 family of transcription factors. Thus, our study is the first to reveal a conserved functional domain controlling nuclear import in IRF2BP2.</p>
    </sec>
    <sec sec-type="methods and materials" id="s2">
      <title>Methods and Materials</title>
      <sec id="s2a">
        <title>Plasmid Constructs</title>
        <p>Human IRF2BP2a (AY278023) was first amplified by PCR with the primers <named-content content-type="gene">5â²-<underline>GGA TCC</underline> GGC TCC TCG GACATG GCC-3â²</named-content> (sense primer, <underline>BamHI</underline>) and <named-content content-type="gene">5â²-<underline>TCT AGA</underline> GTC TCT CTC TTT TTT CAC TTT-3â²</named-content> (antisense primer, <underline>XbaI</underline>) and was then subcloned into TOPO vectors (Invitrogen, Carlsbad, CA). To generate pEGFP-IRF2BP2a, full-length IRF2BP2a was released from TOPO-IRF2BP2a plasmid by BamHI digestion and then subcloned in pEGFP-C1 (Clontech, San Jose, CA). A summary of the GFP-IRF2BP2 fusion constructs is shown in <xref ref-type="fig" rid="pone-0024100-g006">Fig. 6</xref>. To generate the GFP-TEAD4 expression construct, TEAD4 was first amplified by PCR with the following primers: <named-content content-type="gene">5â²- <underline>GAA TTC</underline> TGG AGC CTT GGA GGG CAC GGC</named-content> - 3â² (<underline>EcoRI</underline>) and <named-content content-type="gene">5â²- <underline>GGA TCC</underline> CCG AGT CTC TCA TTC TTT CAC CAG -3â²</named-content> (<underline>BamHI</underline>) and subcloned into pEGFP-C1 vector between EcoRI and BamHI sites. For generating mutant constructs, the IRF2BP2 mutants â 355 <named-content content-type="gene">GAC GAC GAC GAC</named-content> 358 (aspartic acids), TCT 360 TAT (S360A), and TCT 360 GAT (S360D) - flanked between the endogenous PstI and NcoI in IRF2BP2 were ordered from Integrated DNA Technologies (San Diego, CA) as pIDTSMART-IRF2BP2 and were subcloned in pEGFP-IRF2BP2a (Cloning details will be provided upon inquiry). Similarly, a pEGFP-IRF2BP2b construct was generated by swapping a PstI/NcoI fragment of IRF2BP2b into the pEGFP-IRF2BP2a clone. All plasmid constructs were purified by CsCl-banding and their reading frames were verified by sequencing. DsRed-Rab11 WT (Addgene plasmid 12679) and RFP-LAMP1 (Addgene plasmid 1817) expression vectors were obtained from Addgene (Cambridge, MA). Expression vectors for wild type IRF2BP2, S360A and S360D mutants were generated by subcloning a full-length EcoR1 fragment from pEGFP-IRF2BP2 into the pXJ40-CMVHA vector. The mouse VEGFA promoter construct was described previously <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>.</p>
      </sec>
      <sec id="s2b">
        <title>Tissue culture, transient transfections and luciferase assays</title>
        <p>C<sub>2</sub>C<sub>12</sub> myoblasts and African green monkey kidney (CV1) cells were obtained from American Type Culture Collection (Rockville, MD). Cells were maintained in high glucose DMEM with 20% FBS (or 10% FBS for CV1), 100 U/ml penicillin, 100 ug/ml streptomycin. Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and GenJet Reagent (Cat # SL100489- C<sub>2</sub>C<sub>12</sub>, SignaGen Laboratories, Ijamsville, MD) were used to transfect CV1 and C<sub>2</sub>C<sub>12</sub> myoblasts, respectively, according to the manufacturer's instructions. Luciferase assays were conducted as described previously <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref> and luciferase activities were expressed as mean fold Â± SEM relative to the empty pXJ40CMV vector. Differences between fold luciferase activities were compared by Student's t-test and considered significant at p&lt;0.05.</p>
      </sec>
      <sec id="s2c">
        <title>Protein kinase inhibitors</title>
        <p>The protein kinase A (PKA) inhibitor H89 (working concentration: 20 ÂµM, Cat. #: B1427), the inhibitor of phosphoinositide 3-kinases LY294002 (10 ÂµM, L9908), and the MEK1/MEK2 inhibitor U0126 (10 ÂµM, #U120) were from Sigma-Aldrich (Oakville, ON., Canada). The calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor CK-59 (100 ÂµM, #208922) and the ribosomal S6 kinase (RSK) inhibitor SL0101 (10 ÂµM, #559285) were from Calbiochem (Gibbstown, NJ). The cyclin dependent kinase inhibitor olomoucine (10 ÂµM, #V2372) was from Promega (Madison, WI).</p>
      </sec>
      <sec id="s2d">
        <title>Immunofluorescence</title>
        <p>The rabbit polyclonal anti-IRF2BP2 antibody was described previously <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>. Rabbit polyclonal PRDX3 antibody (ab50300) was purchased from Abcam Inc., (Cambridge, MA). Alexa488-conjugated goat anti-mouse and Alexa594-conjugated goat anti-rabbit antibodies were from Santa Cruz Biotechnology Inc., (Santa Cruz, CA). 48-hours post transfection, cells were washed twice with 1x phosphate-buffered saline (PBS; 3.2 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.5 mM KH<sub>2</sub>PO<sub>4</sub>, 1.3 mM KCl, 135 mM NaCl, pH 7.4), fixed in ice-cold methanol at â20Â°C for 10 minutes, washed thrice with 1x PBS, permeabilized by 0.5% Triton-X 100, and washed thrice with 1x PBS. Cells were then counter-stained with 4â²,6-diamidino-2-pheylindole (DAPI, Sigma), mounted on glass slides, and visualized on a Zeiss M1 microscope.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <p>IRF2BP2b is a nuclear protein in mouse C<sub>2</sub>C<sub>12</sub> myoblasts that becomes redistributed to the cytoplasm during muscle differentiation <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>. The nuclear targeting sequence has not been identified in IRF2BP2 so we generated green fluorescent protein (GFP)-IRF2BP2 fusion constructs to enable the identification of sequences necessary and sufficient for this process. The GFP protein is localized to the cytoplasm of C<sub>2</sub>C<sub>12</sub> myoblasts whereas a control construct fusing GFP to the TEAD4 transcription factor is localized to the nucleus of C<sub>2</sub>C<sub>12</sub> myoblasts (<xref ref-type="fig" rid="pone-0024100-g001">Fig. 1A</xref>). The GFP-IRF2BP2a and GFP-IRF2BP2b fusion proteins were detected in the nucleus of C<sub>2</sub>C<sub>12</sub> myoblasts (<xref ref-type="fig" rid="pone-0024100-g001">Fig. 1C,D</xref>). Since the both isoforms localized to the nucleus, we chose IRF2BP2a for subsequent studies.</p>
      <fig id="pone-0024100-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>Green fluorescent protein (GFP) full-length IRF2BP2 fusion constructs are targeted to the nucleus.</title>
          <p>A. GFP alone was localized in the cytoplasm of C<sub>2</sub>C<sub>12</sub> myosblasts. B. A GFP fusion construct with the nuclear-targeted transcription factor TEAD4 was nuclear localized in C<sub>2</sub>C<sub>12</sub> myoblasts. C. GFP-IRF2BP2a was localized to the nucleus of C<sub>2</sub>C<sub>12</sub> myoblasts. D. GFP-IRF2BP2b was also nuclear in C<sub>2</sub>C<sub>12</sub> myoblasts. Nuclei were revealed by DAPI in blue. Scale bar, 50 Âµm.</p>
        </caption>
        <graphic xlink:href="pone.0024100.g001"/>
      </fig>
      <p>Using convenient restriction sites, we found that the N-terminal sequence of IRF2BP2 encoded by exon 1 (amino acids 1-333) was not imported into the nucleus, whereas a fragment encoded largely by exon 2 (amino acids 333â587) was localized in the nucleus (<xref ref-type="fig" rid="pone-0024100-g002">Fig. 2</xref>). A fragment containing amino acids 101â422 was also localized in the nucleus, identifying a nuclear targeting sequence between amino acids 333 and 422. The GFP-IRF2BP2(Ex1) fusion protein was found in cytoplasmic speckles (<xref ref-type="fig" rid="pone-0024100-g002">Fig. 2B,C</xref>). To determine the cellular localization of this fragment, we tested for colocalization with a mitochondrial protein (peroxiredoxin 3, PRDX3), a lysosome associated membrane protein (LAMP) and a Golgi body targeted protein Ras-related protein 11 (Rab11) using specific antibodies. We found that the N-terminal fragment of IRF2BP2 is targeted to the lysosome, and is likely degraded (<xref ref-type="fig" rid="pone-0024100-g002">Fig. 2C</xref>).</p>
      <fig id="pone-0024100-g002" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.g002</object-id>
        <label>Figure 2</label>
        <caption>
          <title>Nuclear localization signal is contained within the C-terminal half of IRF2BP2.</title>
          <p>A. Diagram of GFP fusion IRF2BP2 deletion contructs used to localize the NLS. B. The N-terminal fragment, GFP-IRF2BP2(Ex1) is cytoplasmic, whereas the middle, GFP-IRF2BP2(MscI), and C-terminal, GFP-IRF2BP2(Ex2P), fragments are nuclear in C<sub>2</sub>C<sub>12</sub> myoblasts. C. The N-terminal fragment is targeted to the lysosome in C<sub>2</sub>C<sub>12</sub> myoblasts. Mitochondrial-specific peroxiredoxin 3 (PRDX3) and Golgi body-sepcific Ras-related protein 11 (Rab11) did not, whereas the lysosome-associated membrane protein (LAMP) did co-localize with GFP-IRF2BP2(Ex1). Scale bars, 50 Âµm.</p>
        </caption>
        <graphic xlink:href="pone.0024100.g002"/>
      </fig>
      <p>Given that the C-terminal fragment of IRF2BP2 is targeted to the nucleus, we sought to identify the minimal nuclear localization sequences (NLS) within this fragment. Bioinformatic analyses (<xref ref-type="fig" rid="pone-0024100-g003">Fig. 3A</xref>) suggested two putative NLS in conserved regions of IRF2BP2, one at the N-terminus of exon 2 encoded sequence we called Ex2N, <sup>357</sup>ARKRKP<sup>364</sup> and the other and the C-terminus we called Ex2C, <sup>579</sup>KVKKERD<sup>587</sup>. To evaluate whether these sites are functional, the second exon was further divided into three parts, namely 333-422, 422â587, and 575â587, fused with GFP, and then transiently overexpressed in C<sub>2</sub>C<sub>12</sub> myoblasts. Here, the 333â422 fragment was found in the nucleus (<xref ref-type="fig" rid="pone-0024100-g003">Fig. 3B</xref>), but the C-terminal Ex2C 575â587 fragment or the 422â587 fragment did not. Thus, the Ex2C sequence is not an NLS, nor is a cryptic NLS present in the sequences from amino acids 422 to 587. To authenticate the NLS at Ex.2N, positively charged amino acids were replaced by negatively charged aspartic acids (DDDD) using site-directed mutagenesis (<xref ref-type="fig" rid="pone-0024100-g003">Fig. 3C</xref>). When expressed in C<sub>2</sub>C<sub>12</sub> myoblasts, the aspartic acid mutant remained in the cytoplasm, confirming that the Ex2N NLS in IRF2BP2 is functional (<xref ref-type="fig" rid="pone-0024100-g003">Fig. 3C</xref>).</p>
      <fig id="pone-0024100-g003" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.g003</object-id>
        <label>Figure 3</label>
        <caption>
          <title>Identification of the NLS within the C-terminal half of IRF2BP2.</title>
          <p>A. Two putative NLS sequences were identified in conserved regions of IRF2BP2. Core arginine (R) and lysine (K) sequences are highlighted in yellow. B. GFP fusion constructs with the amino acid positions indicated were tested in C<sub>2</sub>C<sub>12</sub> myoblasts to reveal that the sequence between amino acid 333 and 422 contains the functional NLS of IRF2BP2. C. Site-directed mutagenesis converting the R and K to aspartic acid (D) residues prevented nuclear localization. Scale bar, 50 Âµm.</p>
        </caption>
        <graphic xlink:href="pone.0024100.g003"/>
      </fig>
      <p>A survey of phosphopeptide databases generated from large scale proteomic studies that employed mass spectrometry revealed that IRF2BP2 is phosphorylated at serine 360 (S360), two amino acids downstream of the newly identified Ex2N NLS, in many human cell types (<xref ref-type="table" rid="pone-0024100-t001">Table 1</xref>). To test whether phosphorylation of S360 affects nuclear import of IRF2BP2, we mutagenized the serine to either an alanine (S360A) that cannot be phosphorylated or to an aspartic acid (S360D), that carries a negative charge and mimics phosphorylation. The GFP-IRF2BP2 S360A mutant was localized in the cytoplasm of C<sub>2</sub>C<sub>12</sub> myoblasts. To rule out that the S360A mutant created a cryptic nuclear export signal, leptomycin B (10 nM) was used to block CRM1-dependent nuclear export, but it did not cause nuclear retention of the GFP-IRF2BP2 S360A mutant (<xref ref-type="supplementary-material" rid="pone.0024100.s001">Fig. S1</xref>). Thus, cytosolic localization of the GFP-IRF2BP2 S360A mutant likely results from failure to import rather than a CRM1-dependent nuclear export. In contrast, the GFP-IRF2BP2 S360D mutant was located in the nucleus (<xref ref-type="fig" rid="pone-0024100-g004">Fig. 4A</xref>). During skeletal muscle differentiation of C<sub>2</sub>C<sub>12</sub> cells, we reported previously that IRF2BP2 is partially relocated to the cytoplasm <xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>. Thus, we asked whether the S360D mutant would enforce nuclear retention of IRF2BP2 in C<sub>2</sub>C<sub>12</sub> cells 72 hours after the induction of muscle differentiation. Both the endogenous IRF2BP2 and the GFP fusion protein bearing full-length wild type IRF2BP2 were localized in both the cytoplasm and nucleus, whereas the S360D mutant was exclusively nuclear (<xref ref-type="fig" rid="pone-0024100-g004">Fig. 4B</xref>).</p>
      <fig id="pone-0024100-g004" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.g004</object-id>
        <label>Figure 4</label>
        <caption>
          <title>Phosphorylation of serine 360 controls nuclear localization of IRF2BP2.</title>
          <p>A. Site-directed mutagenesis of serine 360 to alanine (S360A) blocked nuclear localization of IRF2BP2 whereas aspartic acid substitution (S360D) did not differ from wild type and was nuclear localized in C<sub>2</sub>C<sub>12</sub> myoblasts. B. After 72 hours in differentiation medium, the endogenous IRF2BP2 (revealed with IRF2BP2 antibody), as well as GFP-IRF2BP2 (wild type, green), are localized in both the cytoplasm and nucleus of C<sub>2</sub>C<sub>12</sub> myotubes. The S360D mutant was exclusively found in the nucleus in C<sub>2</sub>C<sub>12</sub> myotubes.</p>
        </caption>
        <graphic xlink:href="pone.0024100.g004"/>
      </fig>
      <table-wrap id="pone-0024100-t001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Serine 360 of IRF2BP2 is phosphorylated in multiple human cell types.</title>
        </caption>
        <alternatives>
          <graphic id="pone-0024100-t001-1" xlink:href="pone.0024100.t001"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" rowspan="1" colspan="1">Human Cell line/tissues</td>
                <td align="left" rowspan="1" colspan="1">Identified peptides</td>
                <td align="left" rowspan="1" colspan="1">Reference</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">HeLa (cervical carcinoma)</td>
                <td align="left" rowspan="1" colspan="1">RKPpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Olsen1" ref-type="bibr">[26]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">NCI-H1299 (non-small cell lung cancer)</td>
                <td align="left" rowspan="1" colspan="1">KPpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Tsai1" ref-type="bibr">[28]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">HeLa (cervical carcinoma)</td>
                <td align="left" rowspan="1" colspan="1">KRKRpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Dephoure1" ref-type="bibr">[29]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Embryonic stem cells (male)</td>
                <td align="left" rowspan="1" colspan="1">KPpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-VanHoof1" ref-type="bibr">[30]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">MV4-11 (myeloid)</td>
                <td align="left" rowspan="1" colspan="1">RKPpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Oppermann1" ref-type="bibr">[31]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Jurkat (T lymphocytes)</td>
                <td align="left" rowspan="1" colspan="1">VARTARKRKPpSPEPEGEVGPP</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Mayya1" ref-type="bibr">[27]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td>
                <td align="left" rowspan="1" colspan="1">RKPpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Han1" ref-type="bibr">[32]</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Leukocyte-blood</td>
                <td align="left" rowspan="1" colspan="1">RKPpSPEPEGEVGPPK</td>
                <td align="left" rowspan="1" colspan="1">
<xref rid="pone.0024100-Raijmakers1" ref-type="bibr">[33]</xref>
</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="nt101">
            <label/>
            <p>Fragments analyzed by mass spectrometry were identified by mining online datasets.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>When co-expressed with the transcription factor TEAD1, we reported previously that IRF2BP2 strongly co-activates a mouse VEGFA promoter in African green monkey kidney CV1 cells, where endogenous IRF2BP2 levels are low<xref rid="pone.0024100-Teng1" ref-type="bibr">[6]</xref>. We also observed nuclear exclusion of the S360A mutant of IRF2BP2 and nuclear retention of the S360D mutant in CV1 cells (<xref ref-type="fig" rid="pone-0024100-g005">Fig. 5A</xref>). We next tested whether nuclear exclusion of IRF2BP2 would block and whether forced nuclear retention of IRF2BP2 would enhance mouse VEGF promoter activity in the presence of TEAD1. Compared to wildtype IRF2BP2 co-expressed with TEAD1, not only did the alanine mutant fail to co-activate the VEGFA promoter, as expected, but surprisingly the aspartic acid mutant also failed to co-activate the VEGFA promoter in CV1 cells (<xref ref-type="fig" rid="pone-0024100-g005">Fig. 5B</xref>). We confirmed that TEAD1 and the wild type and the mutant IRF2BP2 proteins were expressed at comparable levels and were of the expected size by immunoblot analysis of transfected CV1 cells (<xref ref-type="fig" rid="pone-0024100-g005">Fig. 5C</xref>). Thus, although the aspartic acid substitution of serine 360 forces nuclear retention of IRF1BP2, it also appears to disrupt the co-activation function of IRF2BP2.</p>
      <fig id="pone-0024100-g005" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.g005</object-id>
        <label>Figure 5</label>
        <caption>
          <title>Despite forced nuclear retention the S360D mutant did not produce a dominantly active form of IRF2BP2.</title>
          <p>A. The S360A mutant of IRF2BP2 was cytoplasmic and the S360D mutant was nuclear in CV1 cells. Scale bar, 50 Âµm. B. The wild type IRF2BP2 augmented TEAD1-dependent activation of the mouse VEGFA promoter in CV1 cells (asterisk, p&lt;0.05). The S360A and the S360D both failed to co-activate VEGFA when co-expressed with TEAD1. Nâ=â3 experiments. C. Immunoblot analysis of protein lysates from transfected CV1 cells revealed similar levels of wild type and mutant IRF2BP2 proteins.</p>
        </caption>
        <graphic xlink:href="pone.0024100.g005"/>
      </fig>
      <p>Currently, we do not know which kinase is responsible for the phosphorylation of S360. From a list of candidate kinases includes protein kinase A (PKA, consensus sequence R-R/K-X-S/T), kinase B (PKB), kinase C (PKC), kinase G (PKG), ribosomal S6 kinase (RSK), extracellular signal-regulated kianses 1/2 (ERK1/2, X-X-S/T-P), calmodulin-dependent protein kinase II (CaMKII, R-X-X-S/T), and Cdc2 (S/T-P-X-R/L), we tested various inhibitors against these kinases to determine whether they would cause cytoplasmic retention of IRF2BP2. However, in no case was IRF2BP2 excluded from the nucleus of C<sub>2</sub>C<sub>12</sub> myoblasts 24 hours post-treatment (<xref ref-type="supplementary-material" rid="pone.0024100.s002">Fig. S2</xref>).</p>
      <p>The diagram shown in <xref ref-type="fig" rid="pone-0024100-g006">Fig. 6A</xref> summarizes our finding of a single phosphorylation-modulated NLS in IRF2BP2. This sequence is conserved across the different paralogous homologs in both humans and zebrafish (<xref ref-type="fig" rid="pone-0024100-g006">Fig. 6B</xref>).</p>
      <fig id="pone-0024100-g006" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0024100.g006</object-id>
        <label>Figure 6</label>
        <caption>
          <title>Identification of the phosphorylation-dependent NLS of IRF2BP2.</title>
          <p>A. Diagram of deletion and mutagenesis constructs used to identify the phosphorylation-dependent NLS. Fusion proteins that are targeted to the nucleus are identified by a +, whereas those that are cytoplasmic are identified by -. Exes (x) represent mutagenized residues that abolish nuclear localization. B. Sequence conservation of the NLS. In all 3 paralogous genes, IRF2BP2, IRF2BP1 and EAP1 in humans (Homo sapiens) and zebrafish (Danio rerio), the NLS and the phosphorylation target sequences are conserved. Asterisks represent identical sequence.</p>
        </caption>
        <graphic xlink:href="pone.0024100.g006"/>
      </fig>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>Nuclear import of IRF2BP2 depends not only on a classical nuclear localization sequence, but also on phosphorylation of serine 360. Although our studies have not identified the protein kinase responsible for this phosphorylation event, the cytoplasmic localization of IRF2BP2 in differentiating skeletal muscle cells suggests that this protein kinase might become down-regulated or inactivated. Preventing nuclear entry of IRF2BP2 by mutating S360A was sufficient to render the protein inactive to regulate VEGFA promoter activity. Surprisingly, forced nuclear localization did not make IRF2BP2 a better transactivator of VEGFA. This result indicates that nuclear localization is not sufficient to ensure transcriptional activity of IRF2BP2 and that the S360D mutation might affect the interaction of IRF2BP2 with a putative transcription cofactor or affect a transactivation function of IRF2BP2.</p>
      <p>Nuclear trafficking is a fundamental and essential mechanism to modulate import and export of RNA and proteins across the nuclear membranes within eukaryotes. This process depends heavily on thousands of protein complexes on the nuclear envelope and the import/export signals on cargo molecules. The classic NLS, composed of a cluster of arginine and lysine residues, has been extensively studied. X-ray crystallography shows that the positive charges from lysine and arginine enhance the binding affinity to negatively charged armadillo pockets of karyopherin-Î± <xref rid="pone.0024100-Fontes1" ref-type="bibr">[14]</xref>. Karyopherin-Î± serves as an adaptor between a cargo protein and karyopherin-Î². Nevertheless, other studies have shown that karyopherin-Î± could directly interact with a cargo protein <xref rid="pone.0024100-Lee1" ref-type="bibr">[15]</xref>. Our study showed that one of two putative sequences was a functional NLS required for IRF2BP2 for nuclear entry.</p>
      <p>Post-translational modifications are important for modulating protein structures or functions for downstream actions in response to environmental cues. One of frequently encountered examples includes phosphorylation <xref rid="pone.0024100-Harrison1" ref-type="bibr">[17]</xref>â<xref rid="pone.0024100-Sheng1" ref-type="bibr">[20]</xref>. Database mining revealed that IRF2BP2 is phosphorylated at several serine residues in addition to serine 360 (data not shown). Serine 360 is located two amino acids downstream from the NLS (<xref ref-type="fig" rid="pone-0024100-g006">Fig. 6B</xref>) and our site-directed mutagenesis studies are consistent with phosphorylation at this site being necessary for nuclear entry, because blocking this process by mutagenesis led to perinuclear accumulation of the mutant protein (S360A), even in the presence of the NLS. A possible explanation is that phosphorylation of the serine residue is likely to alter IRF2BP2 protein structure, strengthening the stability of IRF2BP2-karyopherin complexes for crossing the nuclear membrane. Many examples for phosphorylation-dependent nuclear entry exist in eukaryotes, including import of extracellular signal-regulated kinase-1/2 (ERK1/2) <xref rid="pone.0024100-Lidke1" ref-type="bibr">[21]</xref>, histone deacetylase 4 (HDAC4) <xref rid="pone.0024100-deSouza1" ref-type="bibr">[22]</xref>, forkhead box M1 (FOXM1) <xref rid="pone.0024100-Ma1" ref-type="bibr">[23]</xref>, and adenomatous polyposis cell (APC) protein <xref rid="pone.0024100-Zhang1" ref-type="bibr">[24]</xref>. However, we were not able to identify the kinase that phosphorylates S360. This might be due to phosphorylation of S360 by more than one kinase. For example, low-density lipoprotein (LDL)-receptor-related protein 6 (LRP6) can be phosphorylated by both glycogen synthase kinase 3 (GSK3) and casein kinase I (CKI) <xref rid="pone.0024100-Zeng1" ref-type="bibr">[25]</xref>.</p>
      <p>The discovery of a single classical NLS in IRF2BP2 may help to predict the NLS in both IRF2BP1 and EAP1. The results show a striking similarity in sequence conservation, with both paralogs having a conserved NLS and a conserved phosphorylation target in an adjacent serine (<xref ref-type="fig" rid="pone-0024100-g006">Fig. 6B</xref>). Mass-spectrometry confirms that both S384 of IRF2BP1 <xref rid="pone.0024100-Olsen1" ref-type="bibr">[26]</xref> and S547 of EAP1 <xref rid="pone.0024100-Mayya1" ref-type="bibr">[27]</xref> are phosphorylated in vivo. It remains to be formally proven whether both NLS signals and the serine residues provide similar functions as those observed in this study for IRF2BP2. It is worth noting that the locations of these sequences are not in currently known functional domains. This is consistent with previous studies showing that an NLS is most often away from other functional motifs to avoid interference. Our study provides important insight into the position of the nuclear targeting signals in the IRF2BP2 family of transcription factors.</p>
    </sec>
    <sec sec-type="supplementary-material" id="s5">
      <title>Supporting Information</title>
      <supplementary-material content-type="local-data" id="pone.0024100.s001">
        <label>Figure S1</label>
        <caption>
          <p>
<bold>Blocking CRM1 nuclear export did not cause retention of the S360A mutant of IRF2BP2</bold>. C<sub>2</sub>C<sub>12</sub> myoblasts transfected with GFP-IRF2BP2 (S360A) were treated with vehicle (1 Âµl 70% methanol in 1 ml medium, Control) or leptomycin B (10 nM, LMB). Scale bar, 10 Âµm.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0024100.s001.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0024100.s002">
        <label>Figure S2</label>
        <caption>
          <p>
<bold>Various protein kinase inhibitors failed to block nuclear import of endogenous IRF2BP2.</bold> C<sub>2</sub>C12 myoblasts were treated with vehicle (DMSO) or inhibitors of protein kinases for 24 hours. Scale bar, 50 Âµm. See <xref ref-type="sec" rid="s2">Methods and Materials</xref> for descriptions and concentrations of protein kinase inhibitors.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0024100.s002.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding: </bold>This work was supported by operating grants from the Canadian Institutes of Health Research (AFRS MOP77682, HHC MOP179197), by a grant in aid from the Heart and Stroke Foundation of Ontario (HHC NA6301), by an Ontario Graduate Scholarship in Science and Technology (A.T.) and by a scholarship from Taiba University, Saudi Arabia (N.A.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pone.0024100-Childs1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Childs</surname><given-names>KS</given-names></name><name><surname>Goodbourn</surname><given-names>S</given-names></name></person-group>
<year>2003</year>
<article-title>Identification of novel co-repressor molecules for Interferon Regulatory Factor-2.</article-title>
<source>Nucleic Acids Res</source>
<volume>31</volume>
<fpage>3016</fpage>
<lpage>3026</lpage>
<pub-id pub-id-type="pmid">12799427</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Heger1">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heger</surname><given-names>S</given-names></name><name><surname>Mastronardi</surname><given-names>C</given-names></name><name><surname>Dissen</surname><given-names>GA</given-names></name><name><surname>Lomniczi</surname><given-names>A</given-names></name><name><surname>Cabrera</surname><given-names>R</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis.</article-title>
<source>J Clin Invest</source>
<volume>117</volume>
<fpage>2145</fpage>
<lpage>2154</lpage>
<pub-id pub-id-type="pmid">17627301</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Yeung1">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yeung</surname><given-names>KT</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lomniczi</surname><given-names>A</given-names></name><name><surname>Ojeda</surname><given-names>SR</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>A Novel Transcription Complex That Selectively Modulates Apoptosis of Breast Cancer Cells through Regulation of FASTKD2.</article-title>
<source>Mol Cell Biol</source>
<volume>31</volume>
<fpage>2287</fpage>
<lpage>2298</lpage>
<pub-id pub-id-type="pmid">21444724</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Tinnikov1">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tinnikov</surname><given-names>AA</given-names></name><name><surname>Yeung</surname><given-names>KT</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Samuels</surname><given-names>HH</given-names></name></person-group>
<year>2009</year>
<article-title>Identification of a novel pathway that selectively modulates apoptosis of breast cancer cells.</article-title>
<source>Cancer Res</source>
<volume>69</volume>
<fpage>1375</fpage>
<lpage>1382</lpage>
<pub-id pub-id-type="pmid">19190336</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Koeppel1">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koeppel</surname><given-names>M</given-names></name><name><surname>van Heeringen</surname><given-names>SJ</given-names></name><name><surname>Smeenk</surname><given-names>L</given-names></name><name><surname>Navis</surname><given-names>AC</given-names></name><name><surname>Janssen-Megens</surname><given-names>EM</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response.</article-title>
<source>Nucleic Acids Res</source>
<volume>37</volume>
<fpage>322</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">19042971</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Teng1">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teng</surname><given-names>ACT</given-names></name><name><surname>Kuraitis</surname><given-names>D</given-names></name><name><surname>Deeke</surname><given-names>SA</given-names></name><name><surname>Ahmadi</surname><given-names>A</given-names></name><name><surname>Dugan</surname><given-names>SG</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression.</article-title>
<source>Faseb J</source>
<volume>24</volume>
<fpage>4825</fpage>
<lpage>4834</lpage>
<pub-id pub-id-type="pmid">20702774</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Chen1">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Mullett</surname><given-names>SJ</given-names></name><name><surname>Stewart</surname><given-names>AFR</given-names></name></person-group>
<year>2004</year>
<article-title>Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes.</article-title>
<source>J Biol Chem</source>
<volume>279</volume>
<fpage>30800</fpage>
<lpage>30806</lpage>
<pub-id pub-id-type="pmid">15140898</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Yoshida1">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T</given-names></name></person-group>
<year>2008</year>
<article-title>MCAT elements and the TEF-1 family of transcription factors in muscle development and disease.</article-title>
<source>Arterioscler Thromb Vasc Biol</source>
<volume>28</volume>
<fpage>8</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">17962623</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Adam1">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adam</surname><given-names>SA</given-names></name><name><surname>Gerace</surname><given-names>L</given-names></name></person-group>
<year>1991</year>
<article-title>Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import.</article-title>
<source>Cell</source>
<volume>66</volume>
<fpage>837</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="pmid">1653647</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Germain1">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Germain</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>MOS11: A New Component in the mRNA Export Pathway.</article-title>
<source>PLoS Genet</source>
<volume>6</volume>
<fpage>e1001250</fpage>
<pub-id pub-id-type="pmid">21203492</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Paine1">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paine</surname><given-names>PL</given-names></name><name><surname>Moore</surname><given-names>LC</given-names></name><name><surname>Horowitz</surname><given-names>SB</given-names></name></person-group>
<year>1975</year>
<article-title>Nuclear envelope permeability.</article-title>
<source>Nature</source>
<volume>254</volume>
<fpage>109</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">1117994</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Zanta1">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanta</surname><given-names>MA</given-names></name><name><surname>Belguise-Valladier</surname><given-names>P</given-names></name><name><surname>Behr</surname><given-names>JP</given-names></name></person-group>
<year>1999</year>
<article-title>Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>96</volume>
<fpage>91</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">9874777</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Miyamoto1">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Imamoto</surname><given-names>N</given-names></name><name><surname>Sekimoto</surname><given-names>T</given-names></name><name><surname>Tachibana</surname><given-names>T</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><etal/></person-group>
<year>1997</year>
<article-title>Differential modes of nuclear localization signal (NLS) recognition by three distinct classes of NLS receptors.</article-title>
<source>J Biol Chem</source>
<volume>272</volume>
<fpage>26375</fpage>
<lpage>26381</lpage>
<pub-id pub-id-type="pmid">9334211</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Fontes1">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fontes</surname><given-names>MR</given-names></name><name><surname>Teh</surname><given-names>T</given-names></name><name><surname>Riell</surname><given-names>RD</given-names></name><name><surname>Park</surname><given-names>SB</given-names></name><name><surname>Standaert</surname><given-names>RF</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Crystallization and preliminary X-ray diffraction analysis of importin-alpha complexed with NLS peptidomimetics.</article-title>
<source>Biochim Biophys Acta</source>
<volume>1750</volume>
<fpage>9</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">15878698</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Lee1">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Cansizoglu</surname><given-names>AE</given-names></name><name><surname>Suel</surname><given-names>KE</given-names></name><name><surname>Louis</surname><given-names>TH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Rules for nuclear localization sequence recognition by karyopherin beta 2.</article-title>
<source>Cell</source>
<volume>126</volume>
<fpage>543</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="pmid">16901787</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Mosammaparast1">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mosammaparast</surname><given-names>N</given-names></name><name><surname>Jackson</surname><given-names>KR</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Brame</surname><given-names>CJ</given-names></name><name><surname>Shabanowitz</surname><given-names>J</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Nuclear import of histone H2A and H2B is mediated by a network of karyopherins.</article-title>
<source>J Cell Biol</source>
<volume>153</volume>
<fpage>251</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="pmid">11309407</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Harrison1">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>BC</given-names></name><name><surname>Huynh</surname><given-names>K</given-names></name><name><surname>Lundgaard</surname><given-names>GL</given-names></name><name><surname>Helmke</surname><given-names>SM</given-names></name><name><surname>Perryman</surname><given-names>MB</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Protein kinase C-related kinase targets nuclear localization signals in a subset of class IIa histone deacetylases.</article-title>
<source>FEBS Lett</source>
<volume>584</volume>
<fpage>1103</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="pmid">20188095</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Baetz1">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baetz</surname><given-names>A</given-names></name><name><surname>Koelsche</surname><given-names>C</given-names></name><name><surname>Strebovsky</surname><given-names>J</given-names></name><name><surname>Heeg</surname><given-names>K</given-names></name><name><surname>Dalpke</surname><given-names>AH</given-names></name></person-group>
<year>2008</year>
<article-title>Identification of a nuclear localization signal in suppressor of cytokine signaling 1.</article-title>
<source>FASEB J</source>
<volume>22</volume>
<fpage>4296</fpage>
<lpage>4305</lpage>
<pub-id pub-id-type="pmid">18725457</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Kuwahara1">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuwahara</surname><given-names>H</given-names></name><name><surname>Nishizaki</surname><given-names>M</given-names></name><name><surname>Kanazawa</surname><given-names>H</given-names></name></person-group>
<year>2008</year>
<article-title>Nuclear localization signal and phosphorylation of Serine350 specify intracellular localization of DRAK2.</article-title>
<source>J Biochem</source>
<volume>143</volume>
<fpage>349</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="pmid">18084041</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Sheng1">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheng</surname><given-names>T</given-names></name><name><surname>Chi</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name></person-group>
<year>2006</year>
<article-title>Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal.</article-title>
<source>J Biol Chem</source>
<volume>281</volume>
<fpage>9</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">16293631</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Lidke1">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lidke</surname><given-names>DS</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Post</surname><given-names>JN</given-names></name><name><surname>Rieger</surname><given-names>B</given-names></name><name><surname>Wilsbacher</surname><given-names>J</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>ERK nuclear translocation is dimerization-independent but controlled by the rate of phosphorylation.</article-title>
<source>J Biol Chem</source>
<volume>285</volume>
<fpage>3092</fpage>
<lpage>3102</lpage>
<pub-id pub-id-type="pmid">19920141</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-deSouza1">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>deSouza</surname><given-names>N</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Dura</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>TV</given-names></name><name><surname>Marks</surname><given-names>AR</given-names></name></person-group>
<year>2007</year>
<article-title>A function for tyrosine phosphorylation of type 1 inositol 1,4,5-trisphosphate receptor in lymphocyte activation.</article-title>
<source>J Cell Biol</source>
<volume>179</volume>
<fpage>923</fpage>
<lpage>934</lpage>
<pub-id pub-id-type="pmid">18056410</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Ma1">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>RY</given-names></name><name><surname>Tong</surname><given-names>TH</given-names></name><name><surname>Cheung</surname><given-names>AM</given-names></name><name><surname>Tsang</surname><given-names>AC</given-names></name><name><surname>Leung</surname><given-names>WY</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c.</article-title>
<source>J Cell Sci</source>
<volume>118</volume>
<fpage>795</fpage>
<lpage>806</lpage>
<pub-id pub-id-type="pmid">15671063</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Zhang1">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>White</surname><given-names>RL</given-names></name><name><surname>Neufeld</surname><given-names>KL</given-names></name></person-group>
<year>2000</year>
<article-title>Phosphorylation near nuclear localization signal regulates nuclear import of adenomatous polyposis coli protein.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>97</volume>
<fpage>12577</fpage>
<lpage>12582</lpage>
<pub-id pub-id-type="pmid">11050185</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Zeng1">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Doble</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation.</article-title>
<source>Nature</source>
<volume>438</volume>
<fpage>873</fpage>
<lpage>877</lpage>
<pub-id pub-id-type="pmid">16341017</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Olsen1">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>JV</given-names></name><name><surname>Blagoev</surname><given-names>B</given-names></name><name><surname>Gnad</surname><given-names>F</given-names></name><name><surname>Macek</surname><given-names>B</given-names></name><name><surname>Kumar</surname><given-names>C</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.</article-title>
<source>Cell</source>
<volume>127</volume>
<fpage>635</fpage>
<lpage>648</lpage>
<pub-id pub-id-type="pmid">17081983</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Mayya1">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mayya</surname><given-names>V</given-names></name><name><surname>Lundgren</surname><given-names>DH</given-names></name><name><surname>Hwang</surname><given-names>SI</given-names></name><name><surname>Rezaul</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.</article-title>
<source>Sci Signal</source>
<volume>2</volume>
<fpage>ra46</fpage>
<pub-id pub-id-type="pmid">19690332</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Tsai1">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CF</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name><name><surname>Chen</surname><given-names>YR</given-names></name><name><surname>Lai</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>PY</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics.</article-title>
<source>J Proteome Res</source>
<volume>7</volume>
<fpage>4058</fpage>
<lpage>4069</lpage>
<pub-id pub-id-type="pmid">18707149</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Dephoure1">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dephoure</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Villen</surname><given-names>J</given-names></name><name><surname>Beausoleil</surname><given-names>SA</given-names></name><name><surname>Bakalarski</surname><given-names>CE</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>A quantitative atlas of mitotic phosphorylation.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>105</volume>
<fpage>10762</fpage>
<lpage>10767</lpage>
<pub-id pub-id-type="pmid">18669648</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-VanHoof1">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Hoof</surname><given-names>D</given-names></name><name><surname>Munoz</surname><given-names>J</given-names></name><name><surname>Braam</surname><given-names>SR</given-names></name><name><surname>Pinkse</surname><given-names>MW</given-names></name><name><surname>Linding</surname><given-names>R</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Phosphorylation dynamics during early differentiation of human embryonic stem cells.</article-title>
<source>Cell Stem Cell</source>
<volume>5</volume>
<fpage>214</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">19664995</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Oppermann1">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oppermann</surname><given-names>FS</given-names></name><name><surname>Gnad</surname><given-names>F</given-names></name><name><surname>Olsen</surname><given-names>JV</given-names></name><name><surname>Hornberger</surname><given-names>R</given-names></name><name><surname>Greff</surname><given-names>Z</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Large-scale proteomics analysis of the human kinome.</article-title>
<source>Mol Cell Proteomics</source>
<volume>8</volume>
<fpage>1751</fpage>
<lpage>1764</lpage>
<pub-id pub-id-type="pmid">19369195</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Han1">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis.</article-title>
<source>Electrophoresis</source>
<volume>31</volume>
<fpage>1080</fpage>
<lpage>1089</lpage>
<pub-id pub-id-type="pmid">20166139</pub-id></element-citation>
      </ref>
      <ref id="pone.0024100-Raijmakers1">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raijmakers</surname><given-names>R</given-names></name><name><surname>Kraiczek</surname><given-names>K</given-names></name><name><surname>de Jong</surname><given-names>AP</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Heck</surname><given-names>AJ</given-names></name></person-group>
<year>2010</year>
<article-title>Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer.</article-title>
<source>Anal Chem</source>
<volume>82</volume>
<fpage>824</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="pmid">20058876</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>